干眼症市场规模、份额和成长分析（按产品、剂型、通路和地区划分）－2025-2032年产业预测

预计到 2023 年，全球干眼症市场规模将达到 77 亿美元，到 2024 年将成长至 83.1 亿美元，到 2032 年将成长至 152.6 亿美元，预测期（2025-2032 年）的复合年增长率为 7.9%。

全球干眼症 (DES) 市场分析显示，治疗方式正显着从非处方药转向针对发炎机制的处方药。创新处方药技术正在涌现，专注于缓解疾病疗法，以解决睑板腺功能障碍、眼表发炎和泪膜不稳定等问题。干眼症盛行率的不断上升，尤其是在老年人和伴随其他疾病的人群中，进一步推动了这一增长。 60 岁及以上人口的快速成长加剧了全球干眼症发病率的上升。目前，数百万人患有严重的干眼症，欧洲和东亚等地区的病例呈现上升趋势。这个不断变化的市场凸显了对有效且有针对性的治疗方案的需求。

推动全球干眼症治疗市场发展的因素

全球干眼症市场受到人口老化和干眼症盛行率上升的显着影响。随着越来越多的老年人需要持续的眼部护理，处方笺和非处方药的需求也相应增长。此外，萤幕使用时间的激增可能会即时推动润滑剂销售的成长，并持续增加对治疗性介入的需求。北美目前是领先的市场，展现出强劲的收入成长潜力。因此，该市场为创新治疗方法和诊断服务提供了广阔的发展空间，确保了该领域持续的机会。

限制全球干眼症治疗市场的因素

儘管干眼症 (DED) 的盛行率很高，但许多患者仍未被诊断和治疗。在许多情况下，患者放弃就医，选择自行服用非处方药。这种趋势限制了用于有效控制和治疗疾病的药物的收入潜力，也使得患者难以过渡到处方药治疗。确诊患者中服用处方药的比例相对较低，阻碍了更先进、更昂贵的治疗方案的整体成长潜力。因此，这些因素是全球干眼症市场的重要阻碍因素因素。

全球干眼症市场趋势

全球干眼症市场正经历显着的转变，治疗重点从单纯缓解症状转向针对潜在疾病过程的处方药物和疗法。临床医生越来越倾向于采用专注于改善泪膜稳定性和抑制发炎路径的创新治疗方法。胜肽类、神经兴奋剂和缓释缓释性等新型药物的出现，以及突破性临床试验的发展，都推动了这项转变。此外，专科诊所和个人化处方笺的兴起正在重塑治疗模式，将重点转向长期管理策略，预计将显着推动市场成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

干眼症市场规模（依产品划分）及复合年增长率（2025-2032 年）

• 市场概览
• 非处方（OTC）人工泪液和润滑剂
• 处方药
• 泪小管栓塞
• 膳食补充剂和Omega-3补充剂
• 自体血清和血液来源的泪液替代品

干眼症市场规模（依剂型划分）及复合年增长率（2025-2032 年）

• 市场概览
• 眼药水
• 软膏和凝胶

干眼症市场规模（依分销管道划分）及复合年增长率（2025-2032 年）

• 市场概览
• 医院药房
• 独立药房和药品商店
• 线上药局和电子商务入口网站

干眼症市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• AbbVie Inc.（United States）
• Bausch+Lomb（Canada）
• Novartis AG（Switzerland）
• Johnson & Johnson Services, Inc.（United States）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Alcon Inc.（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Otsuka Pharmaceutical Co., Ltd.（Japan）
• Viatris Inc.（United States）
• Kala Pharmaceuticals, Inc.（United States）
• Novaliq GmbH（Germany）
• AFT Pharmaceuticals（New Zealand）
• Aldeyra Therapeutics（United States）
• OASIS Medical（United States）
• Akorn Operating Company LLC（United States）
• Nicox SA（France）
• Ocular Therapeutix, Inc.（United States）
• Mitotech SA（Luxembourg）
• Tarsus Pharmaceuticals, Inc.（United States）
• Stuart Therapeutics（United States）

结论与建议

Global Dry Eye Syndrome Market size was valued at USD 7.7 billion in 2023 and is poised to grow from USD 8.31 billion in 2024 to USD 15.26 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

Market insights for the global dry eye syndrome (DES) segment indicate a notable shift towards prescription therapies targeting inflammatory mechanisms, moving away from over-the-counter lubricants. Innovative prescription drug technologies are emerging, focusing on disease-modifying treatments that address concerns like meibomian gland dysfunction, ocular surface inflammation, and tear-film instability. This growth is further fueled by the increasing prevalence of dry eye disease, particularly among the aging population and those with related health conditions. The demographic of individuals over 60 is expanding rapidly, contributing to the rising incidence globally. Currently, millions are affected by significant dry eye, with cases rising in regions such as Europe and East Asia, highlighting the necessity for effective, targeted treatment options in this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dry Eye Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dry Eye Syndrome Market Segments Analysis

Global Dry Eye Syndrome Market is segmented by Product, Dosage Form, Distribution Channel and region. Based on Product, the market is segmented into Over the Counter (OTC) Artificial Tears & Lubricants, Prescription Drugs, Punctual Plugs, Nutraceuticals & Omega-3 Supplements and Autologous Serum & Blood-Derived Tear Substitutes. Based on Dosage Form, the market is segmented into Eye Drops and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Independent Pharmacies & Drug Stores and Online Pharmacies & E-Commerce Portals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is significantly influenced by the growing aging population alongside an increase in the prevalence of dry eye conditions. As more elderly individuals require ongoing eye care, there is a corresponding demand for both prescription and over-the-counter treatments. Additionally, the surge in screen time among individuals contributes to an immediate uptick in lubricant sales and may create a sustained need for therapeutic interventions. North America currently stands out as a leading market, indicating a robust potential for revenue growth. Consequently, the landscape is ripe for innovative treatments and diagnostic services, ensuring ongoing opportunities in this sector.

Restraints in the Global Dry Eye Syndrome Market

Despite the widespread occurrence of dry eye disease (DED), a significant number of patients remain undiagnosed and untreated. Often, individuals choose not to consult a healthcare professional, opting instead for self-treatment using over-the-counter eye drops. This behavior limits the revenue potential for medications specifically developed to manage or progress the condition effectively, while also complicating the transition to prescription treatments. The relatively low percentage of diagnosed patients who receive prescription medication impedes the overall growth potential of utilizing more advanced and costly therapeutic options. Consequently, these factors represent considerable constraints within the global dry eye syndrome market.

Market Trends of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is experiencing a significant trend towards prescription medications and treatments that target the underlying disease process rather than merely alleviating symptoms. Clinicians are increasingly shifting their preference towards innovative therapies that focus on enhancing tear film stability and addressing inflammatory pathways. This evolution is supported by the emergence of new pharmacological options, including peptides, neurostimulatives, and sustained-release formulations, alongside the initiation of groundbreaking clinical trials. Furthermore, the rise of specialty clinics and tailored formularies is redefining treatment paradigms, positioning the market for substantial growth as the focus transitions to long-term management strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Dry Eye Syndrome Market Size by Product & CAGR (2025-2032)

• Market Overview
• Over the Counter (OTC) Artificial Tears & Lubricants
• Prescription Drugs
• Punctual Plugs
• Nutraceuticals & Omega-3 Supplements
• Autologous Serum & Blood-Derived Tear Substitutes

Global Dry Eye Syndrome Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Eye Drops
• Ointments & Gels

Global Dry Eye Syndrome Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Independent Pharmacies & Drug Stores
• Online Pharmacies & E-Commerce Portals

Global Dry Eye Syndrome Market Size & CAGR (2025-2032)

• North America (Product, Dosage Form, Distribution Channel)
  • US
  • Canada
• Europe (Product, Dosage Form, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Dosage Form, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Dosage Form, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Dosage Form, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kala Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novaliq GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AFT Pharmaceuticals (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aldeyra Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OASIS Medical (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akorn Operating Company LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nicox S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitotech S.A. (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tarsus Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stuart Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations